Citi analyst David Lebowitz raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $68 from $65 and keeps a Buy rating on the shares. Mirum reported Q3 financial results, handily beating Street estimates based on stronger than expected Livmarli sales, the analyst tells investors in a research note. The firm says that while reimbursement dynamics pulled forward some revenue in the quarter, Livmarli’s launch continues to demonstrate encouraging growth and increase its contribution towards total franchise sales.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIRM:
- Mirum Pharmaceuticals Reports Strong Q3 Sales Growth
- Mirum Pharmaceuticals reports Q3 EPS (30c), consensus (45c)
- MIRM Upcoming Earnings Report: What to Expect?
- Mirum Pharmaceuticals price target raised to $49 from $47 at Leerink
- Mirum Pharmaceuticals granted Breakthrough Therapy Designation for volixibat